Mga Batayang Estadistika
| CIK | 821995 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Juniper Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 31, 2018 |
JNP / Juniper Pharmaceuticals, Inc. 15-12B 15-12B United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-10352 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. POS AM POS AM As filed with the Securities and Exchange Commission on August 14, 2018 Registration No. |
|
| August 14, 2018 |
Amended and Restated Certificate of Incorporation of Juniper Pharmaceuticals, Inc. EX-3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JUNIPER PHARMACEUTICALS, INC. FIRST: The name of the corporation is Juniper Pharmaceuticals, Inc. SECOND: The address of the corporation’s registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808. The name of the corporation’s registered agent at such |
|
| August 14, 2018 |
Amended and Restated Bylaws of Juniper Pharmaceuticals, Inc. EX-3.2 Exhibit 3.2 JUNIPER PHARMACEUTICALS, INC. BYLAWS (ADOPTED AUGUST 14, 2018) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board |
|
| August 14, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-10352 5902758596 (State or Other Jurisdiction of Incorporation) ( |
|
| August 14, 2018 |
CTLT / Catalent Inc. SC TO-T/A SC TO-T/A 1 d601586dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Juniper Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Catalent Boston, Inc. A wholly owned subsidiary of Catalent Pharma Solutions, Inc. A wholly own |
|
| August 14, 2018 |
EX-99.(a)(5)(E) Exhibit (a)(5)(E) Media Contacts: Chris Halling Catalent, Inc. +44 (0) 7580 41073 [email protected] Investor Contact: Thomas Castellano Catalent, Inc. (732) 537-6325 [email protected] Richard Kerns NEPR +44 (0) 161 728 5880 [email protected] Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc. SOMERSET, N.J., August 14, 2018 – Cata |
|
| August 14, 2018 |
JNP / Juniper Pharmaceuticals, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. |
|
| August 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporatio |
|
| August 9, 2018 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results Signs Agreement to be Acquired by Catalent, Inc. CRINONE® Revenues Increased 12% and Juniper Pharma Services (JPS) Revenues Increased 41% for the Six-months Ended June 30, 2018 vs. Prior Year BOSTON, August 9, 2018 — Juniper Pharmaceuticals, Inc. (Nasdaq:JNP), a diversified healthcare company w |
|
| August 9, 2018 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. AMENDMENT NO. 2 TO MANUFACTU |
|
| August 9, 2018 |
Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXCLUSIVE LICENSE AGREEMENT |
|
| August 9, 2018 |
Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. SUPPLY AGREEMENT This Agreem |
|
| August 9, 2018 |
JNP / Juniper Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10352 JUNIPER PHARMACEUTICALS, |
|
| August 6, 2018 |
EX-99.(a)(5)(D) Exhibit (a)(5)(D) Letter to Employee Holders of Stock Options with respect to Offer to Purchase All Outstanding Shares of Common Stock of Juniper Pharmaceuticals, Inc. at $11.50 Per Share of Common Stock, Net in Cash, Pursuant to the Offer to Purchase dated July 17, 2018 by Catalent Boston, Inc. a wholly owned subsidiary of Catalent Pharma Solutions, Inc. THE OFFER AND WITHDRAWAL R |
|
| August 6, 2018 |
CTLT / Catalent Inc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Juniper Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Catalent Boston, Inc. A wholly owned subsidiary of Catalent Pharma Solutions, Inc. A wholly owned subsidiary of Catalent, Inc. |
|
| July 31, 2018 |
CTLT / Catalent Inc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Juniper Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Catalent Boston, Inc. A wholly owned subsidiary of Catalent Pharma Solutions, Inc. A wholly owned subsidiary of Catalent, Inc. |
|
| July 31, 2018 |
JNP / Juniper Pharmaceuticals, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Juniper Pharmaceuticals, Inc. (Name of Subject Company) Juniper Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title o |
|
| July 17, 2018 |
EX-99.(e)(2) Exhibit (e)(2) PERSONAL AND CONFIDENTIAL February 16, 2018 Catalent Pharma Solutions, LLC 14 Schoolhouse Road Somerset, NJ 08873 Ladies and Gentlemen: In connection with your consideration of a possible negotiated business combination transaction between Juniper Pharmaceuticals, Inc. (the “Company”) and you or one of your Affiliates (as defined below) (the “Possible Transaction”), you |
|
| July 17, 2018 |
JNP / Juniper Pharmaceuticals, Inc. SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 17, 2018 |
EX-99.(A)(1)(C) 4 d777114dex99a1c.htm EX-99.(A)(1)(C) Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase All Outstanding Shares of Common Stock of Juniper Pharmaceuticals, Inc. at $11.50 Per Share of Common Stock, Net in Cash, Pursuant to the Offer to Purchase dated July 17, 2018 by Catalent Boston, Inc. a wholly owned subsidiary of Catalent Pharma Solutions, Inc. THE OFFER AND |
|
| July 17, 2018 |
EX-99.(A)(1)(A) 2 d777114dex99a1a.htm EX-99.(A)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of Juniper Pharmaceuticals, Inc. at $11.50 Per Share of Common Stock, Net in Cash by Catalent Boston, Inc., a wholly owned subsidiary of Catalent Pharma Solutions, Inc. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, A |
|
| July 17, 2018 |
EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated July 17, 2018, and the related Letter of Transmittal, and any amendment or supplement to such Offer to Purchase or Letter of Transmittal. Purchaser is not aware of a |
|
| July 17, 2018 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Juniper Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Catalent Boston, Inc. A wholly owned subsidiary of Catalent Pharma Solutions, Inc. A wholly owned subsidiary of Catalent, Inc. (Names of Filing Pe |
|
| July 17, 2018 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) Letter to Clients with respect to Offer to Purchase All Outstanding Shares of Common Stock of Juniper Pharmaceuticals, Inc. at $11.50 Per Share of Common Stock, Net in Cash, Pursuant to the Offer to Purchase dated July 17, 2018 by Catalent Boston, Inc. a wholly owned subsidiary of Catalent Pharma Solutions, Inc. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 |
|
| July 17, 2018 |
Exhibit (a)(1)(D) Letter to Brokers and Dealers with respect to Offer to Purchase All Outstanding Shares of Common Stock of Juniper Pharmaceuticals, Inc. |
|
| July 17, 2018 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of Juniper Pharmaceuticals, Inc. at $11.50 Per Share of Common Stock, Net in Cash, Pursuant to the Offer to Purchase dated July 17, 2018 by Catalent Boston, Inc. a wholly owned subsidiary of Catalent Pharma Solutions, Inc. The undersigned represents that I (we) have full authority to surrender without restrict |
|
| July 9, 2018 |
EX-99.1 Exhibit 99.1 Media Contacts: |
|
| July 9, 2018 |
SC TO-C As filed with the Securities and Exchange Commission on July 9, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 3, 2018 |
EX-99.2 Exhibit 99.2 Catalent, Inc. John Chiminski 14 Schoolhouse Road Chair & Chief Executive Officer Somerset, NJ 08873 T (732) 537-6200 F (732) 537-5932 www.catalent.com July 3, 2018 Dear Juniper Team, As you heard today from Nikin Patel, Catalent is excited about the prospect of joining your great team with ours. I wanted to reach out to you directly to tell you a little more about our company |
|
| July 3, 2018 |
EX-99.1 Exhibit 99.1 Juniper Town Hall JONATHAN ARNOLD PRESIDENT, ORAL DRUG DELIVERY 03.07.18 DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied.TM We’re excited to have your business join ours! Why Juniper? An early-phase EU development hub to complement our San Diego, CA and Somerset, NJ development Centers of Excellence A strong source of new molecules for our manuf |
|
| July 3, 2018 |
SC TO-C As filed with the Securities and Exchange Commission on July 3, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 3, 2018 |
Key Messages for Employees Juniper Pharma / Catalent EX-99.1 Exhibit 99.1 Key Messages for Employees Juniper Pharma / Catalent JULY 3, 2018 Earlier today we announced that we have entered into a definitive agreement to be acquired by Catalent, Inc., the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. Unanimously approved by our board of directors, this is the culm |
|
| July 3, 2018 |
EX-99.2 Exhibit 99.2 Catalent, Inc. 14 Schoolhouse Road Somerset, NJ 08873 T (732) 537-6200 F (732) 537-5932 www.catalent.com John Chiminski Chair & Chief Executive Officer July 3, 2018 Dear Juniper Team, As you heard today from Nikin Patel, Catalent is excited about the prospect of joining your great team with ours. I wanted to reach out to you directly to tell you a little more about our company |
|
| July 3, 2018 |
JNP / Juniper Pharmaceuticals, Inc. SC14D9C SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Juniper Pharmaceuticals, Inc. (Name of Subject Company) Juniper Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.01 per Share (Title of Class of Securities) 48203L107 |
|
| July 3, 2018 |
EX-99.1 2 d855255dex991.htm EX-99.1 Exhibit 99.1 Media Contacts: Chris Halling Catalent, Inc. +44 (0) 7580 41073 [email protected] Investor Contact: Thomas Castellano Catalent, Inc. (732) 537-6325 [email protected] Richard Kerns NEPR +44 (0) 161 728 5880 [email protected] Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc. $133 Million Deal Adds European Early Development |
|
| July 3, 2018 |
SC TO-C 1 d855255dsctoc.htm SC TO-C As filed with the Securities and Exchange Commission on July 3, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Juniper Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) Catalent Boston, Inc. A wholly owned subsidiary o |
|
| July 3, 2018 |
JNP / Juniper Pharmaceuticals, Inc. SC14D9C SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Juniper Pharmaceuticals, Inc. (Name of Subject Company) Juniper Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.01 per Share (Title of Class of Securities) 48203L107 |
|
| July 3, 2018 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: CATALENT PHARMA SOLUTIONS, INC., CATALENT BOSTON, INC. AND JUNIPER PHARMACEUTICALS, INC. Dated as of July 2, 2018 The Agreement and Plan of Merger (the “Agreement”) contains representations, warranties and covenants that were made only for purposes of the Agreement and as of specific dates; were solely for the benefit of the parties to |
|
| July 3, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2018 CATALENT, INC. |
|
| July 3, 2018 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: CATALENT PHARMA SOLUTIONS, INC., CATALENT BOSTON, INC. AND JUNIPER PHARMACEUTICALS, INC. Dated as of July 2, 2018 The Agreement and Plan of Merger (the “Agreement”) contains representations, warranties and covenants that were made only for purposes of the Agreement and as of specific dates; were solely for the benefit of the parties to |
|
| July 3, 2018 |
8-K 1 d674537d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-10352 5902758596 (State or other jurisdict |
|
| July 3, 2018 |
Amendment to the Amended and Restated By-laws of Juniper Pharmaceuticals, Inc. EX-3.1 Exhibit 3.1 AMENDMENT NO. 2 TO THE AMENDED AND RESTATED BY-LAWS OF JUNIPER PHARMACEUTICALS, INC. (the “Corporation”) Effective July 2, 2018 The Bylaws of the Corporation shall be amended as follows: 1. Article VII, Section 5 (“Exclusive Jurisdiction of Delaware Courts”) as set forth below is hereby inserted in the Bylaws immediately following Article VII, Section 4 thereof: “SECTION 5. EXCL |
|
| July 3, 2018 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Signs Definitive Agreement to be Acquired by Catalent, Inc. for $11.50 Per Share in Cash BOSTON July 3, 2018 — Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service contract development and manufacturing organization (CDMO) Juniper Pharma Servic |
|
| May 10, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| May 10, 2018 |
EX-99.1 EXHIBIT 99.1 Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results Core Businesses Driving Strong Financial Performance CRINONE® Revenues Increased 30% and Juniper Pharma Services (JPS) Revenues Increased 55% Year-over-Year Conference Call at 8:30 a.m. EST Today BOSTON, May 10, 2018 — Juniper Pharmaceuticals (Nasdaq:JNP), a diversified healthcare company with c |
|
| May 10, 2018 |
JNP / Juniper Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10352 JUNIPER PHARMACEUTICALS |
|
| May 10, 2018 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. SUPPLY AGREEMENT This Supply |
|
| April 27, 2018 |
JNP / Juniper Pharmaceuticals, Inc. 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 1-10352 Juniper |
|
| April 25, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporatio |
|
| April 25, 2018 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience -Company Eligible to Receive Up to $43.75 Million in Milestones for Each IVR Candidate, Plus Royalties on Future Sales- BOSTON, April 25, 2018 — Juniper Pharmaceuticals, Inc. (Nasdaq:JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fe |
|
| March 21, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporatio |
|
| March 9, 2018 |
Subsidiaries of the Company (filed herewith) Exhibit 21 Subsidiaries of the Company Columbia Laboratories (Bermuda) Ltd. Juniper Pharmaceuticals (France) SARL Juniper Pharmaceuticals (UK) Limited Juniper Pharma Services Limited (UK) |
|
| March 9, 2018 |
JNP / Juniper Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 1-10352 JUNIPER PHARMACEUTICALS, INC |
|
| March 8, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation |
|
| March 8, 2018 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results Full Year CRINONE® Revenues Increased 20% and Juniper Pharma Services (JPS) Revenues Increased 32% Year-over-Year Ended 2017 Cash Flow Positive; Company Expects Trend to Continue in 2018 Conference Call at 8:30 a.m. EST Today BOSTON, March 8, 2018 — Juniper Pharmaceuticals (Nasdaq:JNP), a diversifie |
|
| February 5, 2018 |
Juniper Pharmaceuticals to Explore Strategic Alternatives EX-99.1 2 d537334dex991.htm EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals to Explore Strategic Alternatives BOSTON, January 31, 2018 — Juniper Pharmaceuticals, Inc. (“Juniper” or the “Company”) (Nasdaq: JNP), a diversified healthcare company focused on women’s health, today announced that it is exploring strategic alternatives in order to enhance shareholder value. The Company has engaged Rothschil |
|
| February 5, 2018 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| January 8, 2018 |
JNP / Juniper Pharmaceuticals, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2018 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) ( |
|
| January 8, 2018 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE? Supply Agreement with Merck KGaA, Darmstadt, Germany BOSTON, January 08, 2018 ? Juniper Pharmaceuticals (Nasdaq:JNP), a diversified healthcare company focused on women?s health, today announced the extension of its supply agreement for CRINONE? (progesterone gel) with an affiliate of Merck KGaA, Darm |
|
| November 7, 2017 |
JNP / Juniper Pharmaceuticals, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| November 7, 2017 |
EX-99.2 Exhibit 99.2 Event ID: Event Name: JNP?Juniper Pharmaceuticals Q3 2017 Financial Results Call Event Date: 2017-11-02 Officers and Speakers Heather Savelle; Argot Partners, LLC; Senior Vice President Alicia Secor; Juniper Pharmaceuticals, Inc.; President & CEO Jeff Young; Juniper Pharmaceuticals, Inc.; CFO Nikin Patel; Juniper Pharmaceuticals, Inc.; COO Analysts Michael Higgins, ROTH Capita |
|
| November 7, 2017 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results CRINONE? Revenues Increased 19% and Juniper Pharma Services Revenues Increased 38% Year-over-Year Implemented Strategic Reprioritization BOSTON, November 2, 2017 ? Juniper Pharmaceuticals (Nasdaq:JNP), a diversified healthcare company focused on women?s health, today announced financial results |
|
| November 2, 2017 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results CRINONE? Revenues Increased 19% and Juniper Pharma Services Revenues Increased 38% Year-over-Year Implemented Strategic Reprioritization BOSTON, November 2, 2017 ? Juniper Pharmaceuticals (Nasdaq:JNP), a diversified healthcare company focused on women?s health, today announced financial results |
|
| November 2, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| November 2, 2017 |
JNP / Juniper Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10352 JUNIPER PHARMACEUTI |
|
| November 2, 2017 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, the “Agreement”) is effective as of November 1, 2017, and is entered into by and between Juniper Pharmaceuticals, Inc., a Delaware corporation having its corporate offices at 33 Arch St, Suite 31 |
|
| November 2, 2017 |
Exhibit 10.2 THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT is made this 1st day of November, 2017 (the “Effective Date”). BETWEEN: (1) Juniper Pharma Services, Limited (company number 3397582) whose registered office is at 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire NG8 6PX (“the Company”); and (2) DR. NIKIN PATEL of 6 Sefton Drive, Mapperley Park, Nottingham, NG3 5ER ( |
|
| November 2, 2017 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, the “Agreement”) is effective as of November 1, 2017 (the “Effective Date”), and is entered into by and between Juniper Pharmaceuticals, Inc., a Delaware corporation having its corporate offices |
|
| September 19, 2017 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Announces Strategic Reprioritization - Changes Designed to Drive Continued Growth in Core Businesses of Crinone? and Juniper Pharma Services, Focus R&D Strategy ? BOSTON, September 18, 2017 ? Juniper Pharmaceuticals (Nasdaq:JNP), a women?s health therapeutics company, today announced a corporate reprioritization to allow the Company to focus its resourc |
|
| September 19, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2017 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (C |
|
| September 11, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2017 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorpora |
|
| August 3, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2017 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporatio |
|
| August 3, 2017 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating Results CRINONE? Revenues Increased 30% and Juniper Pharma Services Revenues increase 30% Year-over-Year BOSTON, August 3, 2017 ? Juniper Pharmaceuticals (Nasdaq:JNP), a women?s health therapeutics company, today announced financial results for the three-month period ended June 30, 2017. Cash and cash |
|
| August 3, 2017 |
JNP / Juniper Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10352 JUNIPER PHARMACEUTICALS, |
|
| July 5, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2017 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-10352 59-2758596 (State or other jurisdiction (Commission (I.R |
|
| June 21, 2017 |
Juniper Pharmaceuticals DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, |
|
| May 11, 2017 |
Juniper Pharmaceuticals DEF 14A jnp-def14a20170630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? |
|
| May 4, 2017 |
Juniper Pharmaceuticals 10-Q (Quarterly Report) jnp-10q20170331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-10352 JUN |
|
| May 4, 2017 |
Juniper Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2017 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Comm |
|
| May 4, 2017 |
EX-99.1 EXHIBIT 99.1 Juniper Pharmaceuticals Reports First Quarter 2017 Financial and Operating Results Revenue from Core Business Increased 17% Year-over-Year CRINONE? Revenues Increased 22% and Juniper Pharma Services Revenues Rose 25% in Local Currency Compared to First Quarter of 2016 BOSTON, May 4, 2017 ? Juniper Pharmaceuticals (Nasdaq:JNP), a women?s health therapeutics company, today annou |
|
| May 4, 2017 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, this “Agreement”) is effective as of April 12, 2017 (the “Effective Date”), and is entered into by and between Juniper Pharmaceuticals, Inc., a Delaware corporation having its corporate offices a |
|
| May 4, 2017 |
Exhibit 10.6 JUNIPER PHARMACEUTICALS, INC. AMENDED AND RESTATED 2015 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Award Agreement sets forth the terms and conditions of Stock Units granted pursuant to the provisions of the Amended and Restated 2015 Long-Term Incentive Plan (the “Plan”) of Juniper Pharmaceuticals, Inc. (the “Company”) to the Participant whose name appears bel |
|
| May 4, 2017 |
Exhibit 10.1 Addendum to Transition and Consulting Agreement WHEREAS, Juniper Pharmaceuticals, Inc. (the “Company”) and Frank C. Condella, Jr. (the “Executive”), are parties to that certain Transition and Consulting Agreement, dated as of July 19, 2016 (the “Consulting Agreement”); and WHEREAS, the Company and the Executive desire to amend the Consulting Agreement as set forth herein as of March 1 |
|
| May 4, 2017 |
Exhibit 10.5 PERFORMANCE STOCK UNIT AWARD AGREEMENT JUNIPER PHARMACEUTICALS, INC. AMENDED AND RESTATED 2015 LONG-TERM INCENTIVE PLAN THIS AGREEMENT (the “Agreement”) is made effective as of the day of , 20[] (hereinafter called the “Date of Grant”), between Juniper Pharmaceuticals, Inc., a Delaware corporation (hereinafter called the “Company”), and (hereinafter called the “Participant”): R E C I |
|
| May 4, 2017 |
Exhibit 10.4 THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT is made this 27th day of April, 2017 (the “Effective Date”). BETWEEN: (1) Juniper Pharma Services, Limited (company number 3397582) whose registered office is at 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire NG8 6PX (“the Company”); and (2) DR. NIKIN PATEL (“you”). IT IS AGREED as follows 1. DEFINITIONS 1.1 In thi |
|
| May 4, 2017 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.2 3 jnp-ex102372.htm EX-10.2 Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, the “Agreement”) is effective as of April 12, 2017 (the “Effective Date”), and is entered into by and between Juniper Pharmaceuticals, Inc., a Delaware corporat |
|
| May 1, 2017 |
Juniper Pharmaceuticals 10-K/A (Annual Report) 10-K/A 1 jnp-10ka20161231.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co |
|
| March 7, 2017 |
AMENDMENT NO. 2 TO LICENSE AGREEMENT Exhibit 10.32 AMENDMENT NO. 2 TO LICENSE AGREEMENT THIS AMENDMENT NO. 2 TO LICENSE AGREEMENT (this “Amendment”) is entered into as of November 10, 2016 (the “Amendment No. 2 Effective Date”) by and among Juniper Pharmaceuticals, Inc., as successor to Columbia Laboratories, Inc., a Delaware corporation (“Juniper”), Columbia Laboratories (Bermuda) Ltd., a Bermuda corporation (“Columbia”), and Allerg |
|
| March 7, 2017 |
Juniper Pharmaceuticals 10-K (Annual Report) jnp-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 1-10352 JUNIPER |
|
| March 7, 2017 |
Exhibit 21 Subsidiaries of the Company Columbia Laboratories (Bermuda) Ltd. Juniper Pharmaceuticals (France) SARL Juniper Pharmaceuticals (UK) Limited Juniper Pharma Services Limited (UK) |
|
| March 7, 2017 |
EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results Revenue from Core Business Increased 17% Year-over-Year Plan to File Three INDs in the First Half of 2018 Remains on Track Conference Call at 8:30 a.m. EST Today BOSTON, MA ? March 7, 2017 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health |
|
| March 7, 2017 |
AMENDMENT NO. 2 TO PURCHASE AND COLLABORATION AGREEMENT Exhibit 2.2 AMENDMENT NO. 2 TO PURCHASE AND COLLABORATION AGREEMENT THIS AMENDMENT NO. 2 TO THE PURCHASE AND COLLABORATION AGREEMENT (this “Amendment”) is entered into as of November 10, 2016 (the “Amendment No. 2 Effective Date”) by and among Juniper Pharmaceuticals, Inc., formerly known as Columbia Laboratories, Inc., a Delaware corporation (“Juniper”), Allergan Sales, LLC, as assignee of Covent |
|
| March 7, 2017 |
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 Exhibit 31(i).2 Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, Jeffrey E. Young, certify that: 1. I have reviewed this Annual Report on Form 10-K of Juniper Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| March 7, 2017 |
Exhibit 10.31 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, this “Agreement”) is entered into by and between Columbia Laboratories, Inc., a Delaware corporation having its corporate offices at 4 Liberty Square, Boston, MA, 02109 (the “Company”), and Bridget A. Martell, MD MA (“Executive”). WITNE |
|
| March 7, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2017 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Co |
|
| March 7, 2017 |
Consent of Independent Registered Public Accounting Firm Exhibit 23.2 Consent of Independent Registered Public Accounting Firm Juniper Pharmaceuticals, Inc. Boston, Massachusetts We hereby consent to the incorporation by reference in the Registration Statements on Forms S3 (Nos. 333-206928, 333-169599, 333-75275, 333-125671, 333-132803, 333-140107, 333-37976, 333-155530, and 333-38230) and Form S-8 (Nos. 333-152008, 333-188647, 333-205723, 333-116072, 3 |
|
| March 7, 2017 |
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 Exhibit 31(i).1 Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, Alicia Secor certify that: 1. I have reviewed this Annual Report on Form 10-K of Juniper Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| March 7, 2017 |
AMENDMENT No. 2 TO THE AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT Exhibit 10.19 AMENDMENT No. 2 TO THE AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT This Amendment to the Amended and Restated License and Supply Agreement is made and entered into as of this 12th day of December, 2016, by and between Columbia Laboratories (Bermuda) Limited, a Bermuda corporation having its principal place of business at Canon’s Court, 22 Victoria Street, PO Box HM 1179, Hamilt |
|
| December 23, 2016 |
EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THE EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, the ?Agreement?) is effective as of December 19, 2016, and is entered into by and between Juniper Pharmaceuticals, Inc., a Delaware corporation having its corporate offices at 33 Arch St, Suite 3110, Boston, MA, 02110 (the ?Compan |
|
| December 23, 2016 |
Juniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial Officer EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial Officer BOSTON, MA Dec. 20, 2016 Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (Juniper or the Company), a womens health therapeutics company, today announced the appointment of Jeffrey Young as Chief Financial Officer, Treasurer and Secretary effective January 1, 2017. Mr. Y |
|
| December 23, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorpora |
|
| December 23, 2016 |
EX-10.2 Exhibit 10.2 JUNIPER PHARMACEUTICALS, INC. INDUCEMENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT THIS AGREEMENT (the ?Agreement?) is made effective as of the day of January, 2017 (hereinafter called the ?Date of Grant?), between Juniper Pharmaceuticals, Inc., a Delaware corporation (hereinafter called the ?Company?), and Jeffrey Young (hereinafter called the ?Participant?), as a material in |
|
| November 16, 2016 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Monetizes U.S. Crinone Royalty Stream with Allergan ? Transaction Provides $11 Million of Non-Dilutive Cash to Juniper ? Boston, MA ? November 15, 2016 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health therapeutics company, today announced it has entered into an agreement with its partner, Allerga |
|
| November 16, 2016 |
8-K 1 d298306d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdict |
|
| November 15, 2016 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Reports Third Quarter 2016 Financial Results ? Conference call at 8:30 a.m. EST today ? BOSTON, MA ? November 15, 2016 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health therapeutics company, today announced financial results for the three- and nine- month periods ended September 30, 2016. Recent h |
|
| November 15, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Co |
|
| November 14, 2016 |
Juniper Pharmaceuticals 10-Q/A (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File N |
|
| November 14, 2016 |
Juniper Pharmaceuticals FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 14, 2016 |
Juniper Pharmaceuticals 10-Q/A (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| November 14, 2016 |
Juniper Pharmaceuticals 10-K/A (Annual Report) 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 14, 2016 |
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 EX-31.i.1 Exhibit 31(i).1 Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, Alicia Secor certify that: 1. I have reviewed this Annual Report on Form 10-K/A of Juniper Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| November 14, 2016 |
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 EX-31.i.2 Exhibit 31(i).2 Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, George O. Elston, certify that: 1. I have reviewed this Annual Report on Form 10-K/A of Juniper Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| November 14, 2016 |
EX-21 Exhibit 21 Subsidiaries of the Company Columbia Laboratories (Bermuda) Ltd. Juniper Pharmaceuticals (France) SA Juniper Pharmaceuticals (UK) Limited Juniper Pharma Services Limited (UK) |
|
| November 10, 2016 |
Juniper Pharmaceuticals NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| October 31, 2016 |
CORRESP October 31, 2016 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Juniper Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed March 10, 2016 File No. 001-10352 Dear Mr. Rosenberg: This letter sets forth the response of Juniper Phar |
|
| October 24, 2016 |
Juniper Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 18, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporat |
|
| September 29, 2016 |
CORRESP September 29, 2016 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Juniper Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed March 10, 2016 File No. 001-10352 Dear Mr. Rosenberg: Reference is made to the letter dated August 31, |
|
| September 14, 2016 |
CORRESP September 14, 2016 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Juniper Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed March 10, 2016 File No. 001-10352 Dear Mr. Rosenberg: Reference is made to the letter dated August 31, |
|
| September 1, 2016 |
S-8 As filed with the Securities and Exchange Commission on September 1, 2016 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 1, 2016 |
EX-99.4 Exhibit 99.4 JUNIPER PHARMACEUTICALS, INC. AMENDED AND RESTATED 2015 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT This Award Agreement sets forth the terms and conditions of Shares of Stock granted pursuant to the provisions of the Amended and Restated 2015 Long-Term Incentive Plan (the ?Plan?) of Juniper Pharmaceuticals, Inc. (the ?Company?) to the Participant whose name appe |
|
| September 1, 2016 |
EX-99.2 Exhibit 99.2 JUNIPER PHARMACEUTICALS, INC. AMENDED AND RESTATED 2015 LONG-TERM INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD AGREEMENT THIS AGREEMENT (the ?Agreement?) is made effective as of the [DAY] day of [MONTH], [YEAR], (hereinafter called the ?Date of Grant?), between Juniper Pharmaceuticals, Inc., a Delaware corporation (hereinafter called the ?Company?), and [NAME] (hereinafter c |
|
| September 1, 2016 |
Exhibit 99.3 JUNIPER PHARMACEUTICALS, INC. AMENDED AND RESTATED 2015 LONG-TERM INCENTIVE PLAN INCENTIVE STOCK OPTION AWARD AGREEMENT THIS AGREEMENT (the Agreement) is made effective as of the [DAY] day of [MONTH], [YEAR], (hereinafter called the Date of Grant), between Juniper Pharmaceuticals, Inc., a Delaware corporation (hereinafter called the Company), and [NAME] (hereinafter called the |
|
| August 17, 2016 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Juniper Pharmaceuticals Reports Results from Phase 2b Clinical Trial of COL-1077 Lidocaine Vaginal Gel in Gynecologic Procedure Pain BOSTON, MA ? August 17, 2016 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health therapeutics company, today announced that a recently completed Phase 2b clinical trial evaluating its |
|
| August 17, 2016 |
Juniper Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporati |
|
| August 4, 2016 |
Juniper Pharmaceuticals FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 4, 2016 |
Juniper Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (C |
|
| August 4, 2016 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Reports Second Quarter 2016 Financial Results ? Revenues increased 16% year-over-year as product pipeline advances ? ? Conference call at 8:30 a.m. EDT today ? BOSTON, MA ? August 4, 2016 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health therapeutics company, today announced financial and other re |
|
| August 1, 2016 |
Power of Attorney I, Alicia Secor, hereby authorize and designate George O. Elston, with full power of substitution, as my true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and director of Juniper Pharmaceuticals, Inc., a Delaware corporation (the Company), Forms 3, 4, and 5 in accordance with Section 16(a) |
|
| July 28, 2016 |
Juniper Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation |
|
| July 28, 2016 |
EX-10.1 EXHIBIT 10.1 Juniper Pharmaceuticals, Inc. Amended and Restated 2015 Long-Term Incentive Plan 1. Purpose. The Juniper Pharmaceuticals, Inc. Amended and Restated 2015 Long-Term Incentive Plan (the ?Plan?) is intended to provide incentives which will attract, retain and motivate highly competent persons as non-employee directors, officers, employees, and certain consultants and advisors of J |
|
| July 20, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation |
|
| July 20, 2016 |
EX-10.3 Exhibit 10.3 TRANSITION AND CONSULTING AGREEMENT THIS AGREEMENT is made as of July 19, 2016, by and between Juniper Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Frank C. Condella, Jr. (the ?Executive?). WHEREAS, Executive currently serves as the Company?s President and Chief Executive Officer, as well as a member of the Company?s Board of Directors (the ?Board?); WHER |
|
| July 20, 2016 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THE EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, the Agreement) is made as of July 19, 2016, effective as of August 1, 2016 (the Effective Date), and is entered into by and between Juniper Pharmaceuticals, Inc., a Delaware corporation having its corporate offices at 33 Arch St, Suit |
|
| July 20, 2016 |
Juniper Pharmaceuticals Appoints Alicia Secor President and Chief Executive Officer EX-99.1 5 d224513dex991.htm EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Appoints Alicia Secor President and Chief Executive Officer BOSTON, MA – July 20, 2016 — Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (“Juniper” or the “Company”), a women’s health therapeutics company, today announced that its Board of Directors has appointed veteran healthcare executive Alicia Secor as its Pres |
|
| July 20, 2016 |
EX-10.2 Exhibit 10.2 JUNIPER PHARMACEUTICALS, INC. INDUCEMENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT THIS AGREEMENT (the ?Agreement?) is made effective as of the 20th day of July, 2016 (hereinafter called the ?Date of Grant?), between Juniper Pharmaceuticals, Inc., a Delaware corporation (hereinafter called the ?Company?), and Alicia Secor (hereinafter called the ?Participant?), as a material i |
|
| June 22, 2016 |
Juniper Pharmaceuticals DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 15, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation |
|
| June 15, 2016 |
EX-16.1 Exhibit 16.1 June 13, 2016 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Juniper Pharmaceuticals, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of Juniper Pharmaceuticals, Inc. for the event that oc |
|
| June 2, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| June 2, 2016 |
Juniper Pharmaceuticals Announces Planned Retirement of CEO Frank Condella EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Announces Planned Retirement of CEO Frank Condella BOSTON, MA ? June 2, 2016 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health therapeutics company, today announced that Frank C. Condella, Jr., plans to retire as the Company?s President and Chief Executive Officer (?CEO?) later this year. A search |
|
| May 4, 2016 |
Juniper Pharmaceuticals 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 4, 2016 |
EX-99.1 EXHIBIT 99.1 PRESS RELEASE Juniper Pharmaceuticals Reports First Quarter 2016 Financial Results Product pipeline advanced as revenues increased 45% year-over-year Conference call at 8:30 a.m. EDT today BOSTON, MA ? May 4, 2016 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health therapeutics company, today announced financial results for the three-mo |
|
| May 4, 2016 |
Juniper Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Comm |
|
| April 22, 2016 |
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 EX-31(i).1 Exhibit 31(i).1 Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, Frank C. Condella, Jr. certify that: 1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K of Juniper Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement or omit to state a material fact necessary to make the statemen |
|
| April 22, 2016 |
Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 EX-31(i).2 Exhibit 31(i).2 Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 I, George O. Elston, certify that: 1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K of Juniper Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement or omit to state a material fact necessary to make the statements ma |
|
| April 22, 2016 |
Juniper Pharmaceuticals 10-K/A (Annual Report) 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 24, 2016 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors Experienced Corporate Director with Scientific and Financial Background to Chair JNP Audit Committee BOSTON, MA ? March 24, 2016 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health therapeutics company, today announced the appointment of Mary Ann |
|
| March 24, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Commi |
|
| March 10, 2016 |
Juniper Pharmaceuticals FORM 10-K (Annual Report) FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2016 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results Total revenues increased 16% year-over-year, in line with company guidance Conference call at 8:30 a.m. EST today BOSTON, MA ? March 10, 2016 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?Juniper? or the ?Company?), a women?s health therapeutics company, today announced financia |
|
| March 10, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2016 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (C |
|
| March 10, 2016 |
EX-21 Exhibit 21 Subsidiaries of the Company Columbia Laboratories (Bermuda) Ltd. Juniper Pharmaceuticals (France) SA Juniper Pharmaceuticals (UK) Limited Juniper Pharma Services Limited (UK) |
|
| November 10, 2015 |
EX-99.1 Exhibit 99.1 PRESS RELEASE Juniper Pharmaceuticals Reports Third Quarter 2015 Financial Results Product revenues and Service revenues up 22% and 35% year-over-year, respectively Investor Day November 11, 2015, at 10:00 a.m. EST BOSTON, MA November 10, 2015 Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (Juniper or the Company), a womens health therapeutics company, today announced fi |
|
| November 10, 2015 |
Juniper Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2015 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorpora |
|
| October 30, 2015 |
Power of Attorney Know all by these presents that the undersigned hereby constitutes and appoints each of George O. |
|
| October 20, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2015 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporat |
|
| September 22, 2015 |
Acceleration Request Juniper Pharmaceuticals, Inc. Four Liberty Square Boston, MA 02109 617-639-1500 September 22, 2015 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: Juniper Pharmaceuticals, Inc. ?Request for Acceleration Registration Statement on Form S-3 File No. 333- 206928 Ladies and Gent |
|
| September 14, 2015 |
S-3 1 d48158ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on September 14, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 59-2758596 (State or other jur |
|
| July 22, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2015 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation |
|
| July 22, 2015 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ? FOR IMMEDIATE DISTRIBUTION Juniper Pharmaceuticals Announces Board Changes James Geraghty elected Chairman of the Board; Ann Merrifield appointed to Board Boston, MA ? July 16, 2015 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (the ?Company?), a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women?s heal |
|
| July 17, 2015 |
Juniper Pharmaceuticals, Inc. 2015 Long-Term Incentive Plan EX-4.5 Exhibit 4.5 Juniper Pharmaceuticals, Inc. 2015 Long-Term Incentive Plan 1. Purpose. The Juniper Pharmaceuticals, Inc. 2015 Long-Term Incentive Plan (the ?Plan?) is intended to provide incentives which will attract, retain and motivate highly competent persons as non-employee directors, officers, employees, and certain consultants and advisors of Juniper Pharmaceuticals, Inc., a Delaware cor |
|
| July 17, 2015 |
S-8 As filed with the Securities and Exchange Commission on July 17, 2015 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 10, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2015 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| June 16, 2015 |
Juniper Pharmaceuticals DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, fo |
|
| June 4, 2015 |
Juniper Pharmaceuticals DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 28, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2015 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Com |
|
| May 28, 2015 |
EX-99.1 Exhibit 99.1 PRESS RELEASE ? FOR IMMEDIATE DISTRIBUTION Juniper Pharmaceuticals Appoints James A. Geraghty to Board of Directors Board to Appoint Mr. Geraghty as Chairman Following Annual Meeting of Shareholders Boston, MA ? May 28, 2015 ? Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (?the Company?) today announced that James A. Geraghty has been appointed a director of the Company and is i |
|
| May 6, 2015 |
Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2015 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| May 6, 2015 |
Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results EX-99.1 2 d922346dex991.htm EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results BOSTON, MA — May 6, 2015 — Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (“Juniper” or the “Company”), today announced financial results for the three-month period ended March 31, 2015. First quarter financial highlights include: • Total revenues were $8.3 million, an increase of 19% |
|
| April 13, 2015 |
8-K 1 d906254d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2015 JUNIPER PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction |
|
| April 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2015 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Commissi |
|
| April 3, 2015 |
EX-3.1 Exhibit 3.1 Delaware PAGE 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF ?COLUMBIA LABORATORIES, INC.?, CHANGING ITS NAME FROM ?COLUMBIA LABORATORIES, INC.? TO ?JUNIPER PHARMACEUTICALS, INC.?, FILED IN THIS OFFICE ON THE SECOND DAY OF APRIL, A.D. 2015, AT 1:52 |
|
| April 3, 2015 |
EX-3.2 Exhibit 3.2 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BY-LAWS OF COLUMBIA LABORATORIES, INC. (the ?Corporation?) Effective April 10, 2015 The Bylaws of the Corporation shall be amended as follows: The name of the Corporation, as set forth in the title of the Amended and Restated By-Laws, is amended in its entirety to be replaced with the following: ?JUNIPER PHARMACEUTICALS, INC.? All of t |
|
| April 3, 2015 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Columbia Laboratories, Inc. to Become Juniper Pharmaceuticals, Inc. - Company to Begin Trading as ?JNP? on April 13, 2015 - - Company Updates on COL-1077 - Boston, MA ? April 2, 2015 ? Columbia Laboratories, Inc. (Nasdaq: CBRX) (the ?Company?), today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change wil |
|
| April 1, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2015 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| April 1, 2015 |
EX-99.1 Exhibit 99.1 FINAL Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology Co-Inventors Robert Langer, Sc.D. and William Crowley, M.D. join as Strategic Advisors to Columbia BOSTON, Mar. 30, 2015 /PRNewswire/ ? Columbia Laboratories, Inc. (Nasdaq: CBRX) (?Columbia? or ?the Company?), a specialty pharmaceutical company focused o |
|
| March 18, 2015 |
Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2015 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-10352 (Commission Fil |
|
| March 18, 2015 |
Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results EX-99.1 Exhibit 99.1 Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results BOSTON, March 18, 2015 /PRNewswire/ ? Columbia Laboratories, Inc. (Nasdaq: CBRX) (?Columbia? or the ?Company?), today announced financial results for the three- and twelve-month periods ended December 31, 2014. ?The 11% growth in our 2014 full year revenues was driven in large part by a full year |
|
| January 30, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2015 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (C |
|
| January 30, 2015 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Columbia Laboratories Announces Search For New Board Member, Impending Retirement of Chairman Stephen G. Kasnet; Amendment to Increase Permissible Ownership Levels Under Shareholder Rights Plan BOSTON, Jan. 29, 2015 /PRNewswire/ — Columbia Laboratories, Inc. (Nasdaq: CBRX) (“Columbia” or “the Company”), a specialty pharmaceutical company focused on pharma |
|
| January 30, 2015 |
EX-4.1 Exhibit 4.1 AMENDED AND RESTATED RIGHTS AGREEMENT by and between COLUMBIA LABORATORIES, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Rights Agent Dated as of January 28, 2015 TABLE OF CONTENTS Page Section 1. Certain Definitions 2 Section 2. Appointment of Rights Agent 8 Section 3. Issuance of Right Certificates 8 Section 4. Form of Right Certificates 10 Section 5. Countersigna |
|
| January 12, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2015 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation |
|
| January 12, 2015 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS COLUMBIA LABORATORIES, INC. ARTICLE I. MEETINGS OF STOCKHOLDERS SECTION 1. ANNUAL MEETING. A meeting of stockholders shall be held annually for the election of directors and the transaction of such other business as is related to the purpose or purposes set forth in the notice of meeting on such date as may be fixed by the Board of Directors, or if n |
|
| January 12, 2015 |
AMENDED AND RESTATED BY-LAWS COLUMBIA LABORATORIES, INC. ARTICLE I. MEETINGS OF STOCKHOLDERS EX-3.2.1 Exhibit 3.2.1 AMENDED AND RESTATED BY-LAWS COLUMBIA LABORATORIES, INC. ARTICLE I. MEETINGS OF STOCKHOLDERS SECTION 1. ANNUAL MEETING. A meeting of stockholders shall be held annually for the election of directors and the transaction of such other business as is related to the purpose or purposes set forth in the notice of meeting on such date as may be fixed by the Board of Directors, or |
|
| October 28, 2014 |
Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-10352 (Commiss |
|
| October 28, 2014 |
Columbia Laboratories Reports Third Quarter 2014 Financial Results EX-99.1 2 d810807dex991.htm EX-99.1 Exhibit 99.1 Columbia Laboratories Reports Third Quarter 2014 Financial Results BOSTON, October 28, 2014 /PRNewswire/ — Columbia Laboratories, Inc. (Nasdaq: CBRX) (“Columbia” or “the Company”) today announced financial results for the three and nine-month periods ended September 30, 2014. Third Quarter Financial Highlights • Total revenues of $11.5 million, incl |
|
| September 26, 2014 |
EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, this “Agreement”) is entered into by and between Columbia Laboratories, Inc., a Delaware corporation having its corporate offices at 4 Liberty Square, Boston, MA, 02109 (the “Company”), and George O. Elston (“Executive”). WITNESS |
|
| September 26, 2014 |
Columbia Laboratories Announces Appointment of New Chief Financial Officer EX-99.1 Exhibit 99.1 Contact: Katja Buhrer MBS Value Partners (212) 661-7004 FOR IMMEDIATE RELEASE Columbia Laboratories Announces Appointment of New Chief Financial Officer Boston, September 24, 2014 - Columbia Laboratories, Inc. (Nasdaq: CBRX) (“Columbia” or “the Company”), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to |
|
| September 26, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporat |
|
| August 6, 2014 |
EX-99.1 Exhibit 99.1 COLUMBIA LABORATORIES ANNOUNCES SALE OF IP AND TECHNOLOGY FOR LEGATRIN P.M. TO LIL’ DRUG STORE PRODUCTS BOSTON, MA, August 6, 2014 /PRNewswire/ — Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Lil’ Drug Store Products exercised its option to purchase the Intellectual Property Rights and Technology related to Legatrin P.M. Columbia licensed this product to Lil’ |
|
| August 6, 2014 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| July 31, 2014 |
Columbia Laboratories Reports Second Quarter 2014 Financial Results EX-99.1 2 d769480dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Columbia Laboratories Reports Second Quarter 2014 Financial Results BOSTON, July 31, 2014 /PRNewswire/ — Columbia Laboratories, Inc. (Nasdaq: CBRX) (“Columbia” or “the Company”) today announced financial results for the three and six-month periods ended June 30, 2014. “Second quarter results benefited from the contribution of t |
|
| July 31, 2014 |
Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| May 8, 2014 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (C |
|
| April 29, 2014 |
Columbia Laboratories Reports First Quarter 2014 Financial Results EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Vice President & CFO Columbia Laboratories, Inc. (617) 639-1500 FOR IMMEDIATE RELEASE Columbia Laboratories Reports First Quarter 2014 Financial Results BOSTON, MA – April 29, 2014 - Columbia Laboratories, Inc. (Nasdaq: CBRX) (“Columbia” or “the Company”) today announced financial results for the three-month period ended March 31, 2014. First Quar |
|
| April 29, 2014 |
Financial Statements and Exhibits 8-K 1 d720565d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction o |
|
| March 31, 2014 |
Notice & Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 11, 2014 |
JNP / Juniper Pharmaceuticals, Inc. / Allergan plc - SCHEDULE 13G AMENDMENT NO. 3 Passive Investment Schedule 13G Amendment No. 3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* COLUMBIA LABORATORIES, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 197779101 (CUSIP Number) MARCH 7, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| March 7, 2014 |
8-K 1 d689194d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdicti |
|
| March 7, 2014 |
EX-10.1 Exhibit 10.1 EXECUTION COPY STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”), is entered into as of March 6, 2014 by and between Columbia Laboratories, Inc., a Delaware corporation (the “Company”), and Coventry Acquisition, LLC, a Delaware limited liability company corporation, as successor by conversion to Coventry Acquisition, Inc. (“Coventry”, and together with |
|
| March 7, 2014 |
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Tricia Truehart Vice President & CFO Senior Vice President Columbia Laboratories, Inc. The Trout Group LLC (617) 639-1500 (646) 378-2953 FOR IMMEDIATE RELEASE Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis BOSTON, MA – March 7, 2014 - Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has |
|
| March 5, 2014 |
Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| March 5, 2014 |
Juniper Pharmaceuticals 10-K (Annual Report) 10-K 1 d645099d10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi |
|
| March 5, 2014 |
Columbia Laboratories Reports Fourth Quarter and Full Year 2013 Financial Results EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Vice President & CFO Columbia Laboratories, Inc. (617) 639-1500 FOR IMMEDIATE RELEASE Tricia Truehart Senior Associate The Trout Group LLC (646) 378-2953 Columbia Laboratories Reports Fourth Quarter and Full Year 2013 Financial Results BOSTON, MA – March 5, 2014 - Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results of the |
|
| March 3, 2014 |
Juniper Pharmaceuticals FORM 10-Q/A (Quarterly Report) Form 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 3, 2014 |
Columbia Laboratories Announces Board Changes EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Vice President & CFO Columbia Laboratories, Inc. (617) 639-1500 FOR IMMEDIATE RELEASE Tricia Truehart Senior Vice President The Trout Group LLC (646) 378-2593 Columbia Laboratories Announces Board Changes BOSTON, MA – March 3, 2014—Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Donald H. Hunter, an executive and technology consult |
|
| March 3, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (C |
|
| February 20, 2014 |
EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Tricia Truehart Vice President & CFO Senior Associate Columbia Laboratories, Inc. The Trout Group LLC (617) 639-1500 (646) 378-2593 FOR IMMEDIATE RELEASE Columbia Laboratories, Inc. Announces Restatement of Previously-Issued Unaudited Interim Consolidated Financial Statements for the Three- and Nine-Month Periods Ended September 30, 2013 - Financi |
|
| February 20, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 19, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporatio |
|
| February 13, 2014 |
JNP / Juniper Pharmaceuticals, Inc. / Allergan plc - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* COLUMBIA LABORATORIES, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 197779101 (CUSIP Number) DECEMBER 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 6, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Co |
|
| February 6, 2014 |
EX-10.1 Exhibit 10.1 AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT THIS AMENDMENT (this “Amendment”) to the Manufacture and Supply Agreement dated as of December 8, 2009 (the “Agreement”) is entered into as of the 31st day of December, 2013 (the “Amendment Effective Date”), by and between Columbia Laboratories, (Bermuda) Ltd., a limited company existing and organized under the laws of Bermuda, h |
|
| January 9, 2014 |
EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Tricia Truehart Vice President & CFO Senior Associate Columbia Laboratories, Inc. The Trout Group LLC (617) 639-1500 (646) 378-2593 FOR IMMEDIATE RELEASE Columbia Laboratories Announces Preliminary Fourth Quarter and Year-End 2013 Results Revenue Growth of 12%-14% Expected Year-over-Year BOSTON, MA – January 9, 2014—Columbia Laboratories, Inc. (Na |
|
| January 9, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2014 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| January 9, 2014 |
EX-99.2 Frank Condella President & CEO Columbia Laboratories Columbia Laboratories, Inc. (Nasdaq: CBRX) Molecular Profiles, Ltd. (a wholly-owned subsidiary of Columbia Laboratories) Jonathan Lloyd Jones VP & CFO Columbia Laboratories Dr. Nikin Patel CEO Molecular Profiles * * * * * * Exhibit 99.2 Safe Harbor 2 9 January 2014 This presentation contains forward-looking statements, which statements a |
|
| November 21, 2013 |
Financial Statements and Exhibits - 8-K/A 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2013 Columbia Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-10352 59-2758596 (State or Other Jurisdiction of |
|
| November 21, 2013 |
EX-99.1 Table of Contents Exhibit 99.1 Contents Page Independent Auditor’s Report 1 Profit and Loss Account 2 Balance Sheet 3 Notes to the Financial Statements 4 - 13 Table of Contents Independent Auditor’s Report To the Members of Molecular Profiles Limited We have audited the accompanying financial statements of Molecular Profiles Limited, which comprise the balance sheets as of July 31, 2013 an |
|
| November 21, 2013 |
EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED FINANCIAL INFORMATION On September 12, 2013 Columbia Laboratories, Inc. (“Columbia”) completed the acquisition of Molecular Profiles Limited (“Molecular Profiles”), by acquiring all of the outstanding capital stock of Molecular Profiles. The following unaudited pro forma condensed combined consolidated financial information i |
|
| November 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 11, 2013 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Commi |
|
| November 18, 2013 |
EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Tricia Truehart Vice President & CFO Senior Associate Columbia Laboratories, Inc. The Trout Group LLC (617) 639-1500 (646) 378-2593 FOR IMMEDIATE RELEASE Columbia Laboratories to receive One-time Payment from Actavis for CRINONE U.S. Manufacturing Rights Columbia Retains Royalty Right on U.S. CRINONE Sales BOSTON, MA – November 14, 2013 - Columbia |
|
| November 7, 2013 |
Exhibit 99.1 Contact: Jonathan Lloyd Jones Seth Lewis Vice President & CFO Senior Vice President Columbia Laboratories, Inc. The Trout Group LLC (617) 639-1500 (646) 378-2952 FOR IMMEDIATE RELEASE Columbia Laboratories Reports Third Quarter 2013 Financial Results Management will host Conference Call at 11:00AM EST Today BOSTON, MA – November 7, 2013 – Columbia Laboratories, Inc. (Nasdaq: CBRX) tod |
|
| November 7, 2013 |
Financial Statements and Exhibits 8-K 1 d626562d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdi |
|
| September 18, 2013 |
EX-10.1 Exhibit 10.1 The Secretary of State for Business, Innovation and Skills Department for Business, Innovation and Skills 1 Victoria Street London SW1H 0ET 12 September 2013 Molecular Profiles Ltd Regional Growth Fund Assistance In consideration of the Secretary of State for Business, Innovation and Skills (the “Secretary of State”) being willing, at our request, to make Molecular Profiles Lt |
|
| September 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2013 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) (Com |
|
| September 18, 2013 |
EX-2.1 Exhibit 2.1 DATED September 2013 SHARE PURCHASE AGREEMENT between THE SELLERS and COLUMBIA LABORATORIES, INC. AND MOLECULAR PROFILES LIMITED Contents clause 1. Interpretation 1 2. Columbia Stock 9 3. share subscription moneys 9 4. Sale and purchase 9 5. Payment of Purchase price 10 6. Completion 10 7. Purchase Price Adjustment 12 8. Warranties 12 9. Limitations on claims 13 10. Escrowed Fun |
|
| September 18, 2013 |
Exhibit 99.1 Contact: Jonathan Lloyd Jones Seth Lewis Vice President & CFO Senior Vice President Columbia Laboratories, Inc. The Trout Group LLC (617) 639-1500 (646) 378-2952 FOR IMMEDIATE RELEASE Columbia Laboratories Expands Board of Directors Dr. Frank Armstrong and Dr. Nikin Patel Appointed Directors of the Company and Dr. Martyn Davies Appointed Advisor to its Board of Directors BOSTON, MA – |
|
| September 18, 2013 |
EX-10.2 4 d598523dex102.htm EX-10.2 Exhibit 10.2 THIS EMPLOYMENT AGREEMENT is made this 12 day of September 2013 BETWEEN: (1) MOLECULAR PROFILES LIMITED (company number 3397582) whose registered office is at 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire NG8 6PX (“the Company”); and (2) DR. NIKIN PATEL of 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshir |
|
| September 12, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2013 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-10352 (Commi |
|
| September 12, 2013 |
EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Vice President & CFO Columbia Laboratories, Inc. (617) 639-1500 Seth Lewis Senior Vice President The Trout Group LLC (646) 378-2952 Columbia Laboratories Acquires Molecular Profiles Ltd., a U.K.-Based Provider of Pharmaceutical Formulation Development and Manufacturing Services Transaction Expected to Further Increase Earnings and Cash Flow throug |
|
| September 12, 2013 |
EX-99.2 COLUMBIA LABORATORIES, INC. (NASDAQ: CBRX) ACQUISITION OF MOLECULAR PROFILES LTD. Frank Condella, President & CEO, Columbia Laboratories Jonathan Lloyd Jones, VP & CFO, Columbia Laboratories Dr. Nikin Patel, CEO, Molecular Profiles 12 Sept 2013 Exhibit 99.2 2 Safe Harbor This presentation contains forward-looking statements, which statements are indicated by the words “may,” “will,” “plans |
|
| August 8, 2013 |
Columbia Laboratories Announces One-for-Eight Reverse Stock Split EX-99.1 Exhibit 99.1 Contact: Jonathan Lloyd Jones Seth Lewis Vice President & CFO Senior Vice President Columbia Laboratories, Inc. The Trout Group LLC (617) 639-1500 (646) 378-2952 FOR IMMEDIATE RELEASE Columbia Laboratories Announces One-for-Eight Reverse Stock Split BOSTON, MA – August 8, 2013 – Columbia Laboratories, Inc. (“Columbia” or the “Company”) (NasdaqCM: CBRX) announced a 1-for-8 reve |
|
| August 8, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2013 COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-10352 59-2758596 (State or other jurisdiction of incorporation) |
|
| August 8, 2013 |
EX-4.1 Exhibit 4.1 COLUMBIA LABORATORIES, INC. NUMBER SHARES CL COLUMBIA LABORATORIES, INC. INCORPORATED UNDER THE LAWS SEE REVERSE FOR OF THE STATE OF DELAWARE CERTAIN DEFINITIONS THIS IS TO CERTIFY THAT CUSIP 197779 20 0 IS THE OWNER OF FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK OF THE PAR VALUE OF $.01 PER SHARE OF COLUMBIA LABORATORIES, INC. (hereinafter called the “Corporation”) |
|
| August 8, 2013 |
EX-3.1 Exhibit 3.1 Delaware PAGE 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “COLUMBIA LABORATORIES, INC.”, FILED IN THIS OFFICE ON THE SEVENTH DAY OF AUGUST, A.D. 2013, AT 12:45 O’CLOCK P.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE KENT COUNTY RE |
